Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2000 Oct;67(4):1014-9.
doi: 10.1086/303096. Epub 2000 Sep 12.

Association of HPC2/ELAC2 genotypes and prostate cancer

T R Rebbeck  1 , A H Walker, C Zeigler-Johnson, S Weisburg, A M Martin, K L Nathanson, A J Wein, S B Malkowicz
Affiliations

Association of HPC2/ELAC2 genotypes and prostate cancer

T R Rebbeck et al. Am J Hum Genet. 2000 Oct.

Abstract

HPC2/ELAC2 has been identified as a prostate cancer (CaP) susceptibility gene. Two common missense variants in HPC2/ELAC2 have been identified: a Ser-->Leu change at amino acid 217, and an Ala-->Thr change at amino acid 541. Tavtigian et al. reported that these variants were associated with CaP in a sample of men drawn from families with hereditary CaP. To confirm this report in a sample unselected for family history, we studied 359 incident CaP case subjects and 266 male control subjects that were frequency matched for age and race and were identified from a large health-system population. Among control subjects, the Thr541 frequency was 2.9%, and the Leu217 frequency was 31.6%, with no significant differences in frequency across racial groups. Thr541 was only observed in men who also carried Leu217. The probability of having CaP was increased in men who carried the Leu217/Thr541 variants (odds ratio = 2.37; 95% CI 1.06-5.29). This risk did not differ significantly by family history or race. Genotypes at HPC2/ELAC2 were estimated to cause 5% of CaP in the general population of inference. These results suggest that common variants at HPC2/ELAC2 are associated with CaP risk in a sample unselected for family history or other factors associated with CaP risk.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Agarose gel visualization of (A) the Ser217Leu polymorphism and (B) the Ala541Thr polymorphism. PCR product sizes after restriction enzyme digestion with TaqI (for Ser217Leu) or Fnu4HI (for Ala541Thr) are shown.
See this image and copyright information in PMC

References

Electronic-Database Information

    1. Genome Database, http://www.gdb.org/ (for HPC2/ELAC2)
    1. Online Mendelian Inheritance in Man (OMIM), http://www.ncbi.nlm.nih.gov/Omim/ (for CaP [MIM 176807], HPC1 [MIM 601518], PCAP [MIM 602759], HPCX [MIM 300147], CAPB [MIM 603688], and CYP3A4 [MIM 124010])

References

    1. Berthon P, Valeri A, Cohen-Akenine A, Drelon E, Paiss T, Wohr G, Latil A, Millasseau P, Mellah I, Cohen N, Blanche H, Bellane-Chantelot C, Demenais F, Teillac P, Le Duc A, de Petriconi R, Hautmann R, Chumakov I, Bachner L, Maitland NJ, Lidereau R, Vogel W, Fournier G, Mangin P, Cussenot O (1998) Predisposing gene for early onset prostate cancer, localized on chromosome 1q42.2-43. Am J Hum Genet 62:1416–1424 - PMC - PubMed
    1. Gibbs M, Stanford JL, McIndoe RA, Jarvik GP, Kolb S, Goode EL, Chakrabarti L, Schuster EF, Buckley VA, Miller EL, Brandzel S, Li S, Hood L, Ostrander EA (1999) Evidence for a rare prostate cancer susceptibility locus at chromosome 1p36. Am J Hum Genet 64:776–787 - PMC - PubMed
    1. Giovannuci E, Stampfer MJ, Krithivas K, Brown M, Dahl D, Brufsky A (1997) The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA 94:3320–3323 - PMC - PubMed
    1. Ingles S, Ross RK, Yu MC, Irvine RA, La Pera G, Haile RW, Henderson B (1997) Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 89:166–170 - PubMed
    1. Jaffe JM, Walker AH, MacBride S, Peschel R, Tomaszewski J, Van Arsdalen K, Wein AJ, Malkowicz SB, Rebbeck TR (2000) Association of SRD5A2 genotype and pathologic characteristics of prostate tumors. Cancer Res 60:1626–1630 - PubMed

Publication types

MeSH terms